Access Statistics for Aidan Hollis

Author contact details at EconPapers.

Working Paper File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
A Contractual Approach to the Gray Market 0 0 1 427 1 6 11 2,110
Complementarity, Competition and Institutional Development: The Irish Loan Funds through Three Centuries 0 0 0 295 0 0 4 1,323
Exclusivity Restrictions in Markets with Adverse Selection: The Case of Extended Warranties 0 0 0 106 0 8 8 850
Generic drug pricing in Canada: components of the value-chain 0 0 2 106 0 4 8 334
Microcredit in Pre-Famine Ireland 0 0 2 337 2 10 16 1,783
New Approaches to Rewarding Pharmaceutical Innovation 0 0 0 94 2 5 8 173
Privacy, Driving Data and Automobile Insurance: An Economic Analysis 0 0 0 0 2 7 8 290
Privacy, Driving Data and Automobile Insurance: An Economic Analysis 0 0 0 70 0 5 10 253
Subsidizing the Competition 0 0 0 134 1 4 5 687
The Evolution of A Microcredit Institution: The Irish Loan Funds, 1720 - 1920 0 0 0 324 0 4 9 1,596
Total Working Papers 0 0 5 1,893 8 53 87 9,399


Journal Article File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
A National Formulary for Canada 0 0 1 547 0 5 7 4,118
A contractual approach to the gray market 0 0 0 123 1 4 9 414
An Optional Delinked Reward System: Making Pharmaceutical Innovation Work for Everyone 0 0 0 0 1 5 10 14
Climate impact auctions: an underused tool for green subsidies in the Global South 0 0 0 0 1 4 6 6
Co-authorship and the output of academic economists 0 0 0 72 0 3 9 258
Competition policy in open economies 0 0 0 32 0 3 5 172
Der Green Impact Fund for Technology 0 0 0 3 2 6 10 22
Generic Drug Pricing and Procurement: A Policy for Alberta 0 0 0 4 1 4 4 22
Governance of electricity transmission systems 0 0 0 81 0 5 8 220
How do Brands’ “Own Generics” Affect Pharmaceutical Prices? 0 0 1 191 1 2 8 492
How will recent trade agreements that extend market protections for brand-name prescription pharmaceuticals impact expenditures and generic access in Canada? 0 0 0 2 0 7 9 23
Industrial Concentration, Output, and Trade: An Empirical Exploration 0 0 0 37 0 7 8 112
Making Sure Orphan Drugs Don’t Get Left Behind 0 0 0 3 2 6 8 26
Microcredit in Prefamine Ireland 0 2 2 64 0 4 8 274
Microcredit: What can we learn from the past? 0 0 2 328 0 5 9 977
Microfinance and Famine: The Irish Loan Funds during the Great Famine 0 0 0 98 0 4 9 449
Newton's First Law as Applied to Pharmacies: Why Entry Order Matters for Generics 0 0 3 33 5 10 16 132
Patient income and health innovation 0 0 0 11 0 2 5 43
Predicting patent challenges for small-molecule drugs: A cross-sectional study 0 0 0 0 1 3 4 4
Preliminary Injunctions and Damage Rules in Patent Law 0 0 0 72 1 5 6 337
Price‐cap Regulation, Uncertainty and the Price Evolution of New Pharmaceuticals 0 0 0 9 0 2 5 39
Strategic Implications of Learning by Doing 0 0 0 87 1 3 6 567
Sustainable Financing of Innovative Therapies: A Review of Approaches 0 0 0 15 0 7 10 49
The Anti-Competitive Effects of Brand-Controlled "Pseudo- Generics" in the Canadian Pharmaceutical Market 0 0 0 233 2 6 10 737
The Role of Local Depositors in Controlling Expenses in Small‐Scale Financial Intermediation: An Empirical Analysis 0 0 0 16 0 5 6 89
The economic theory of cost‐effectiveness thresholds in health: Domestic and international implications 0 0 0 2 1 4 7 20
The impact of changing the reference countries on the list prices for patented medicines in Canada: A policy analysis 0 0 0 0 0 1 2 3
The importance of being first: evidence from Canadian generic pharmaceuticals 0 1 6 310 3 10 20 733
The large-scale integration of wind generation: Impacts on price, reliability and dispatchable conventional suppliers 0 0 0 60 3 11 16 177
The life-cycle of a microfinance institution: the Irish loan funds 0 0 0 157 0 5 8 464
The path of least resistance: Paying for antibiotics in non-human uses 0 0 0 6 3 7 9 41
Total Journal Articles 0 3 15 2,596 29 155 257 11,034


Statistics updated 2026-03-04